Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Treatment Market

Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Treatment Market Size, Market Forecast and Outlook By FMI

Summary of the Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Treatment Market

• Demand and Growth Drivers
  • PF-ILD indication approval has expanded antifibrotic treatment access beyond IPF.
  • Progressive phenotype recognition is increasing the eligible patient population.
  • Multidisciplinary team expansion is improving diagnostic accuracy.
• Product and Segment View
  • Anti-fibrotic medications are expected to lead with 47.0% of drug type demand in 2026.
  • Oral administration is expected to represent 53.0% of route demand.
  • Hospital pharmacies are expected to account for 41.0% of distribution.
• Geography and Competitive Outlook
  • South Korea (6.4%) and Japan (6.3%) are expected to lead growth.
  • The USA (6.1%) maintains growth through FDA-approved indication.
  • Companies with PF-ILD specific approval are expected to maintain dominant positions.
• Analyst Opinion
  • The PF-ILD market represents a significant indication expansion for antifibrotic therapy beyond IPF.
  • Nintedanib holds the dominant position through INBUILD evidence and specific approval.
  • The market benefits from growing phenotype-based treatment recognition.
  • Companies with PF-ILD approval and established prescribing infrastructure are expected to maintain leadership.

Key Takeaways, Market Size, and Forecast

• The progressive fibrosing interstitial lung disease (PF-ILD) treatment market was valued at USD 5.3 billion in 2025 and is expected to reach USD 5.7 billion by the end of 2026.
• The market is projected to grow at a CAGR of 6.0% from 2026 to 2036, reaching USD 10.2 billion by 2036.
• The market was valued at USD 5.35 billion in 2025.
• By 2036, the market is expected to reach approximately USD 10.15 billion.
• From 2026 to 2036, the market is projected to expand at a CAGR of 6.0%.
• The market is expected to create an incremental opportunity of USD 4.48 billion between 2026 and 2036.
• In 2026, anti-fibrotic medication is expected to account for 47.0% of the drug type segment, driven by established clinical evidence demonstrating efficacy across multiple ILD subtypes and growing prescribing adoption.
• South Korea (6.4%) and Japan (6.3%) are among the fastest-growing markets globally.

Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Treatment Market Definition

The PF-ILD treatment market covers antifibrotic pharmaceutical treatments and supportive care for managing progressive fibrosing ILD, a clinical phenotype encompassing multiple ILD subtypes that exhibit progressive fibrosis despite standard management.

Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Treatment Market Inclusions

Market scope covers all commercially available PF-ILD treatments categorized by drug type (anti-fibrotic medication, immunosuppressants, corticosteroids, supportive therapies), route of administration (oral, inhaled, intravenous), distribution channel (hospital pharmacies, retail pharmacies, specialty pharmacies), and patient group (IPF-derived PF-ILD, autoimmune ILD-derived, exposure-related, unclassifiable). Revenue coverage spans 2026 to 2036.

Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Treatment Market Exclusions

The scope does not include treatments for non-progressive ILD, general respiratory infection management, or lung transplantation surgical costs.

Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Treatment Market Research Methodology

• Primary Research: FMI analysts conducted interviews with pulmonologists, ILD centre directors, and specialty pharmacy managers.
• Desk Research: Combined data from ILD patient registries, pharmaceutical prescription databases, and respiratory treatment records.
• Market Sizing and Forecasting: Bottom-up sizing across drug type, route of administration, and patient group segments with regional ILD diagnosis rate curves.
• Data Validation: Cross-checked quarterly against ILD registry data, pharmaceutical sales, and respiratory clinic utilization.

Why is the Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Treatment Market Growing?

• Regulatory approval of nintedanib for progressive fibrosing ILD based on INBUILD has established antifibrotic access beyond IPF.
• Growing clinical recognition of the progressive fibrosing phenotype across ILD subtypes is increasing the eligible patient population.
• Expansion of multidisciplinary ILD teams is improving diagnostic accuracy and treatment decisions.

Demand reflects the clinical recognition that progressive fibrosis occurs across multiple ILD subtypes and that antifibrotic therapy provides benefit regardless of underlying diagnosis. The INBUILD trial demonstrated nintedanib efficacy across a range of diagnoses.

Adoption of anti-fibrotic medication leads at 47.0%, driven by nintedanib regulatory approval for PF-ILD expanding the eligible patient population.

Pricing reflects specialty pharmaceutical positioning consistent with IPF treatment pricing, with the broader population creating a larger addressable market.

Market Segmentation Analysis

• Anti-Fibrotic Medication accounts for 47.0% of the drug type segment.
• Oral represents 53.0% of the route of administration segment.
• Hospital Pharmacies leads the distribution channel segment with 41.0% share.

The PF-ILD treatment market is segmented by drug type, route of administration, distribution channel, and patient group. Demand reflects the phenotype-based treatment approach extending antifibrotic therapy across multiple ILD diagnoses exhibiting progressive fibrosis.

Insights into the Anti-Fibrotic Medication Drug Type Segment

Anti-fibrotic medications lead at 47.0% due to INBUILD trial evidence supporting nintedanib efficacy across the progressive fibrosing phenotype, approximately doubling the addressable patient population beyond IPF.

Insights into the Oral Route of Administration Segment

Oral administration represents 53.0% of route demand, reflecting oral nintedanib and pirfenidone formulations enabling outpatient chronic treatment.

Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Treatment Market Drivers, Restraints, and Opportunities

• Regulatory and structural demand drivers are creating sustained procurement patterns.
• Cost and access constraints create segmentation in adoption rates.
• Technology and product development are expanding the addressable market.

The progressive fibrosing interstitial lung disease (pf-ild) treatment market is shaped by regulatory, technology, and procurement dynamics.

PF-ILD Indication Approval

Demand is shaped by nintedanib regulatory approval for progressive fibrosing ILD, extending treatment access beyond IPF.

Progressive Phenotype Recognition

Growth reflects growing clinical recognition that progressive fibrosis is treatable across ILD subtypes.

Multidisciplinary ILD Team Expansion

Adoption is supported by expanding MDT approaches that improve diagnostic accuracy.

Established Antifibrotic Framework

The existing IPF treatment infrastructure provides a ready framework for extending therapy to PF-ILD.

Analysis of Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Treatment Market By Key Countries

Country	CAGR
South Korea	6.4%
Japan	6.3%
USA	6.2%
EU	6.1%
UK	5.8%

Source: FMI analysis based on primary research and proprietary forecasting model

• South Korea leads with 6.4% CAGR.
• Japan at 6.3% reflects expanding capabilities.
• USA (6.2%) and EU (6.1%) maintain steady growth.

The global progressive fibrosing interstitial lung disease (pf-ild) treatment market is expected to grow at 6.0% per year from 2026 to 2036.

Demand Outlook for Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Treatment Market in South Korea

South Korea is expected to grow at 6.4% through 2036, supported by respiratory medicine advancement and PF-ILD diagnostic recognition.

• Respiratory medicine supports specialist treatment.
• PF-ILD recognition increases identified patients.
• Antifibrotic adoption is growing.

Future Outlook for Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Treatment Market in Japan

Japan is expected to grow at 6.3% through 2036, driven by established ILD infrastructure and antifibrotic prescribing experience.

• ILD infrastructure provides specialist management.
• Antifibrotic prescribing experience supports adoption.
• Clinical research advances understanding.

Opportunity Analysis of Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Treatment Market in the United States

The USA is expected to grow at 6.1% through 2036, driven by FDA-approved PF-ILD indication and established ILD specialist networks.

• FDA-approved indication enables access.
• ILD specialist networks provide prescribing expertise.
• Specialty pharmacy supports distribution.

In-depth Analysis of Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Treatment Market in the European Union

The EU is expected to grow at 6.0% through 2036, supported by EMA-approved PF-ILD indication and respiratory research.

• EMA approval enables treatment across member states.
• Research collaboration advances evidence.
• MDT expansion improves decision-making.

Sales Analysis of Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Treatment Market in the United Kingdom

The UK is expected to grow at 5.8% through 2036, supported by NICE evaluation and NHS specialist respiratory services.

• NICE evaluation guides access decisions.
• NHS respiratory services deliver specialist care.
• MDT development improves diagnostics.

Competitive Landscape and Strategic Positioning

• Boehringer Ingelheim leads with an estimated 37.2% market share.
• The competitive landscape includes global and specialized players.
• Entry barriers include regulatory, relationship, and scale factors.

Boehringer Ingelheim leads through Ofev (nintedanib), the only antifibrotic with PF-ILD specific regulatory approval.

Roche Holding AG maintains a position through pirfenidone used off-label in some PF-ILD settings.

Bristol-Myers Squibb and FibroGen compete on antifibrotic pipeline development.

Entry barriers include the dominant nintedanib position, high trial costs, and specialist prescribing relationships.

Key Companies in the Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Treatment Market

Key global companies leading the progressive fibrosing interstitial lung disease (pf-ild) treatment market include:

• Boehringer Ingelheim (Germany) and Roche Holding AG (Switzerland) hold dominant positions through approved antifibrotics.
• Bristol-Myers Squibb (USA) and FibroGen, Inc. (USA) compete on pipeline development.
• Galapagos NV (Belgium), Pliant Therapeutics (USA), and Blade Therapeutics (USA) represent emerging positions.

Competitive Benchmarking: Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Treatment Market

Company	PF-ILD Approval	Clinical Evidence	Specialist Relationships	Geographic Reach
Boehringer Ingelheim	Strong	Strong	Strong	Global
Roche Holding AG	Moderate	Strong	Strong	Global
Bristol-Myers Squibb	Low	Moderate	Strong	Global
FibroGen, Inc.	Low	Moderate	Moderate	N. America, Global
Galapagos NV	Low	Low	Moderate	Europe
Pliant Therapeutics	Low	Low	Low	N. America

Source: Future Market Insights competitive analysis, 2026.

Key Developments in Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Treatment Market

• In 2025, Boehringer Ingelheim announced that its Phase 3 FIBRONEER™-ILD trial for the novel antifibrotic nerandomilast successfully met its primary endpoint.
• In 2025, the PF-ILD market saw continued focus on novel therapeutic pipeline development, with multiple companies initiating or advancing clinical trials for new molecules targeting fibrotic pathways.

Key Players in the Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Treatment Market

Major Global Players

• Boehringer Ingelheim
• Roche Holding AG
• Bristol-Myers Squibb
• FibroGen, Inc.
• Galapagos NV
• Verona Pharma
• Genentech (a Roche subsidiary)

Emerging Players/Startups

• Galapagos NV
• Pliant Therapeutics
• Blade Therapeutics
• Samumed
• Kiniksa Pharmaceuticals

Report Scope and Coverage

Parameter	Details
Quantitative Units	USD 5.67 billion to USD 10.15 billion, at a CAGR of 6.0%
Market Definition	The PF-ILD treatment market covers antifibrotic pharmaceutical treatments and supportive care for managing progressive fibrosing ILD, a clinical phenotype encompassing multiple ILD subtypes that exhibit progressive fibrosis despite standard management.
Regions Covered	North America, Latin America, Europe, East Asia, South Asia and Pacific, Middle East and Africa
Countries Covered	USA, UK, France, Germany, Italy, South Korea, Japan, China, India, 30 plus countries
Key Companies Profiled	Boehringer Ingelheim, Roche Holding AG, Bristol-Myers Squibb, FibroGen, Inc., Galapagos NV, Verona Pharma, Genentech (a Roche subsidiary), Sanofi, Gilead Sciences, AstraZeneca
Forecast Period	2026 to 2036
Approach	Hybrid bottom-up and top-down methodology starting with verified transaction data, projecting adoption velocity across segments and regions.

Market Segmentation Analysis

Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Treatment Market Market Segmented by Drug Type:

• Anti-Fibrotic Medication
• Corticosteroids
• Immune Suppressing
• Others

Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Treatment Market Market Segmented by Route of Administration:

• Oral
• Injectable

Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Treatment Market Market Segmented by Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Treatment Market Market Segmented by Patient Group:

• Idiopathic Pulmonary Fibrosis-Derived PF-ILD
• Connective Tissue Disease-Associated PF-ILD
• Hypersensitivity Pneumonitis-Derived PF-ILD
• Unclassifiable Interstitial Lung Disease

Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Treatment Market Market by Region:

• North America
  • USA
  • Canada
  • Mexico
• Latin America
  • Brazil
  • Chile
  • Rest of Latin America
• Western Europe
  • Germany
  • UK
  • Italy
  • Spain
  • France
  • Nordic
  • BENELUX
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • Hungary
  • Balkan & Baltic
  • Rest of Eastern Europe
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia & New Zealand
  • Rest of South Asia and Pacific
• Middle East & Africa
  • Kingdom of Saudi Arabia
  • Other GCC Countries
  • Turkiye
  • South Africa
  • Other African Union
  • Rest of Middle East & Africa

Research Sources and Bibliography

• 1. American Thoracic Society. (2025). ATS Guidelines: PF-ILD. ATS.
• 2. European Respiratory Society. (2024). ERS Statement on PF-ILD. ERS.
• 3. USA Food and Drug Administration. (2025). FDA Approved: Nintedanib for PF-ILD. FDA.
• 4. National Institute for Health and Care Excellence. (2024). NICE Appraisal: Nintedanib for PF-ILD. NICE.
• 5. World Health Organization. (2024). WHO Classification of ILD. WHO.

This bibliography is provided for reader reference. The full Future Market Insights report contains the complete reference list with publication dates, URLs, and supporting data for all cited works.

This Report Answers

• Estimating the market size and revenue from 2026 to 2036.
• Segmentation by drug type, route of administration, distribution channel, and patient group.
• Regional and country-level insights across more than 30 markets.
• INBUILD evidence and clinical adoption analysis.
• Competitive landscape assessment.
• Investment opportunity identification.
• Treatment protocol and phenotype-based prescribing analysis.
• Data delivery in PDF and Excel formats.